# HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Study · id `cardio:ct-nct04153149` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04153149](<https://clinicaltrials.gov/study/NCT04153149>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04153149

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 655 participants.

## Technical summary

Registry record NCT04153149. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-26 (actual); primary completion 2024-05-08 (actual). Results posted on 2025-10-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 655 participants (enrolled count; ClinicalTrials.gov record NCT04153149, source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)
- Started: 2019-11-26 (actual) (ClinicalTrials.gov record NCT04153149, source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2024-05-08 (actual) (ClinicalTrials.gov record NCT04153149, source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)
- Completion: 2027-01-13 (anticipated) (ClinicalTrials.gov record NCT04153149, source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)
- Results first posted: 2025-10-21 (ClinicalTrials.gov record NCT04153149, source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Canada; Colombia; Croatia; Czechia; Denmark; France; Germany; Hungary; Ireland; Israel; Japan; Latvia; Lebanon; Lithuania; Malaysia; Moldova; Netherlands; Norway; Peru; Poland; Portugal; Saudi Arabia; Slovenia; South Korea; Spain; Sweden; Thailand; United Kingdom (ClinicalTrials.gov record NCT04153149, source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04153149-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Condition: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Drug): Vutrisiran
- Intervention (Drug): Sterile Normal Saline (0.9% NaCl)
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (`cardio:pubmed-39213194`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial (`cardio:pubmed-39566871`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy (`cardio:pubmed-40099776`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B (`cardio:pubmed-40769675`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial (`cardio:pubmed-40770082`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis (`cardio:pubmed-42669069`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B (`cardio:pubmed-42669070`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial (`cardio:pubmed-42616515`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial (`cardio:pubmed-42646924`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e1f228daa32caf58a527782ad2f43f6f761825e70700e025fe58ddc0da70b362
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
